Skip to main content
BioNote, Inc. logo

BioNote, Inc. — Investor Relations & Filings

Ticker · 377740 ISIN · KR7377740006 KO Manufacturing
Open in API
Filings indexed 160 across all filing types
Latest filing 2024-03-20 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 377740

About BioNote, Inc.

https://www.bionote.com/

BioNote, Inc. is a company specializing in in-vitro diagnostics for the animal health industry. It develops, manufactures, and distributes a range of veterinary diagnostic products, including rapid test kits, ELISA kits, point-of-care (POC) analyzers, and biomarker tests. The company's portfolio is based on its research and development of core biological components like antigens and antibodies. Its products are designed for the detection and diagnosis of animal diseases, providing veterinarians with tools for immunochemical and quantitative analysis in clinical settings.

Recent filings

Filing Released Lang Actions
사업보고서 (2023.12)
Interim / Quarterly Report Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for the company '주식회사 바이오노트' (Bionote, Inc.) for the fiscal year ending December 31, 2023. It includes the independent auditor's opinion, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. This is a comprehensive annual financial report, which falls under the 'Interim / Quarterly Report' (IR) category in the provided schema, as it contains the full set of audited financial statements for the fiscal period. FY 2023
2024-03-20 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from Bionote announcing the submission of its audit report. It provides a summary of financial data (assets, liabilities, revenue, profit/loss) and audit opinions for both consolidated and separate financial statements. While it contains financial data, it is a short, standardized regulatory announcement (under 5,000 characters) serving as a notification that the audit report has been submitted to the regulator, rather than the full audit report document itself. Therefore, it falls under the Report Publication Announcement (RPA) category. FY 2023
2024-03-20 Korean
[기재정정]사업보고서 (2023.12)
Annual Report Classification · 100% confidence The document is a '사업보고서' (Business Report) for the company '바이오노트' (BioNote) for the fiscal year 2023. It contains detailed corporate information, financial data, and management disclosures, which corresponds to the standard format of an Annual Report (10-K equivalent in the Korean market). The document also includes a '정정신고' (Correction Report) section, which is a common feature of official annual filings. FY 2023
2024-03-20 Korean
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. This type of filing is specifically used to report insider trading or changes in share ownership by company directors and executives. According to the provided definitions, this corresponds to 'Director's Dealing' (DIRS).
2024-03-13 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Bionote, Inc. It contains the meeting date, location, agenda items (financial statement approval, director appointments, etc.), and information regarding electronic voting and proxy procedures. This document is a formal notice sent to shareholders to provide information and request their participation/votes for the upcoming Annual General Meeting. According to the provided definitions, this fits the 'Proxy Solicitation & Information Statement' (PSI) category, as it serves to inform shareholders and solicit their votes for the meeting.
2024-03-13 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options). It details the issuance of stock options to employees, including the number of shares, exercise price, and legal basis (Commercial Act). This type of disclosure regarding capital structure changes and equity-based compensation is classified as a share issue or capital change announcement.
2024-03-12 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.